Biotechnology

Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia

Phase 2 multicenter, open-label study (NCT07499102) will evaluate the safety and clinical efficacy of CK0801 Tregs in transfusion-dependent aplastic anemia. HOUSTON, April 27, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted reg...

2026-04-27 23:19 4750

CONCEPT MEDICAL ANNOUNCES PRELIMINARY 3-YEAR SIRONA DATA AT CHARING CROSS SYMPOSIUM 2026

LONDON, April 27, 2026 /PRNewswire/ -- Concept Medical Inc. , today announced the presentation of preliminary 3-year follow-up data from theSIRONA randomised trial at the Charing Cross (CX) Symposium 2026, reinforcing its leadership in drug-delivery technologies ...

2026-04-27 23:17 3788

Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026

- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent and not associated with clinically significant ALT elevation. These findi...

2026-04-26 19:00 4915

Servier completes the acquisition of Day One Biopharmaceuticals

* Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma.  * Transaction also includes a strong oncology pipeline of clinical stage assetsin rare cancers with high unmet needs.  * Transaction represents total equity ...

2026-04-23 20:30 3647

Fosun Health Strengthens Regional Presence at GlobalHealth Asia-Pacific Forum 2026, Showcasing "China Solution" and Winning Three Major Awards

JAKARTA, Indonesia, April 23, 2026 /PRNewswire/ -- Fosun Health made a prominent debut at the GlobalHealth Asia-Pacific Healthcare Insights & Leadership Forum 2026, held alongside the GlobalHealth Asia-Pacific Awards 2026 at the Grand Hyatt Jakarta, joining a distinguished community of healthcare...

2026-04-23 16:46 3551

Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer

SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clinical study of its proprietary Nectin-4-targeting ADC (R&D code: 9MW2821) for the treatment of triple-ne...

2026-04-23 16:22 4732

2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations

SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma wil...

2026-04-23 15:02 1307

BioEngine Launches UltraFeed CHO Supplement, Boosting Titers by Up to 48%

SHANGHAI, April 23, 2026 /PRNewswire/ -- Shanghai BioEngine Sci-tech Co., Ltd. announced the launch of UltraFeed, a next-generation fed-batch supplement designed to elevate CHO cell productivity in monoclonal antibody, bispecific, and recombinant protein manufacturing. Across diverse cell lines a...

2026-04-23 09:17 2953

Prestige Biopharma IDC Files Patent for Next-Generation Antibody Delivery Platform 'IDC224'… Driving Innovation in Subcutaneous (SC) Formulations

SEOUL, South Korea, April 23, 2026 /PRNewswire/ -- Prestige Biopharma IDC, the innovative drug research institute of Prestige Biopharma, announced that it has filed a patent for 'IDC224,' a next-generation subcutaneous (SC) delivery platform designed to simultaneously enhance the administration c...

2026-04-23 06:30 4020

GenScript Leaders Named Entrepreneur Of The Year® 2026 New Jersey Finalists

PISCATAWAY, N.J., April 23, 2026 /PRNewswire/ -- GenScript Biotech Corporation today announced that CEO Sherry Shao and Co-Founder Dr. Frank Zhang have been ...

2026-04-23 04:03 1926

AscendCare Medical Clinic Launches Public Awareness Initiative to Normalise Regular Health Screening in Singapore

SINGAPORE, April 22, 2026 /PRNewswire/ -- AscendCare Medical Clinic, a modern healthcare provider based in Tanjong Pagar, today announced a new public education initiative designed to reframe health screenings as a routine and responsible component of personal wellness. The campaign addresses a c...

2026-04-22 14:13 3587

Dayspring Pharma Announces Phase II Trial of CG2001 Foam Met Primary Endpoint in Chinese Adult Men with AGA

BEIJING, April 22, 2026 /PRNewswire/ -- Dayspring Pharma today announced top-line data from its Phase II clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated statistically significant and clinically meaningful results...

2026-04-22 11:09 2663

SynbioTech's L. plantarum FS4722 Emerges as a Potential Preventive Approach for Hyperuricemia

TAIPEI, April 22, 2026 /PRNewswire/ -- SynbioTech announced that its Lactiplantibacillus plantarum FS4722 (L. plantarum FS4722), a probiotic strain isolated from traditional Chinese pickled vegetables, has demonstrated potential to support urate regulation in hyperuricemia. L. plantarum FS4722 h...

2026-04-22 09:30 2906

Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting

CHENGDU, China, April 22, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 29 to June 2. In this meeting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) will present results from three clinical studies, includi...

2026-04-22 08:59 4703

Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine

SHANGHAI, April 22, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC (bulumtatug fuvedotin, R&D code: 9MW2821) for the treatment ...

2026-04-22 08:00 4850

Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program

Five-year collaboration supports consistent clinical supply for Phase 1A/1B GI cancer study PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety t...

2026-04-21 20:00 2872

Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time

SHANGHAI, April 21, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-mab, has successfully passed the on-site GMP inspection conducted by the Jordan Food and Drug Adminis...

2026-04-21 10:00 4608

Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026

SHANGHAI, April 20, 2026 /PRNewswire/ -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myelom...

2026-04-20 18:45 3230

Nuance Pharma Announces Publication of Phase 3 ENHANCE-CHINA Data in the CHEST Journal

Ohtuvayre® (ensifentrine) helped improve lung function in Chinese adult patients in in data published in peer reviewed journal SHANGHAI, April 20, 2026 /PRNewswire/ -- Nuance Pharma ("Nuance" or the "Company") announces that CHEST, the official journal of the American College of Chest Physicians...

2026-04-20 09:00 3726

ACT Genomics Upgrades Clinically Recognized Genomic Test to 101-Gene Panel with 7-Day Turnaround

TAIPEI, April 20, 2026 /PRNewswire/ -- ACT Genomics today announced a significant upgrade to the ACTDrug® series, its next-generation sequencing (NGS) genomic profiling service. The updated panel now covers 101 clinically relevant genes and offers a seven-working-day turnaround time, designed to ...

2026-04-20 09:00 3510
1234567 ... 185